Dr. Patrick Weston, M.D.
Cardiology (Cardiovascular Disease Physician)
At a glance
- Medical school
- University of Pittsburgh School of Medicine (2003)
- Years since graduation
- 23
- In the NPI registry since
- 2006
Licensed in Illinois since 2009, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2003Medical school: University of Pittsburgh School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Cardiovascular Disease Physician primary
FL license ME117606 · IL license 036123912 (first issued 2009; active) -
Hospitalist Physician
FL license ME117606
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Kpw Health LLC (2 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Pindolol | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Industry-funded research
Named as a principal investigator on 12 industry-funded studies in 2025, from 9 companies. The companies reported $393,351 in research payments for these studies, mostly to the institutions running them.
- A Phase III double-blind, randomised, placebo-controlled trial to evaluate liver-related clinical outcomes and safety of once weekly injected survodutide in participants with compensated non-alcoholic steatohepatitis/…
Boehringer Ingelheim International GmbH - A randomised, double-blind, placebo-controlled, multicentre, Phase III trial evaluating long-term efficacy and safety of survodutide weekly injections in adult participants with noncirrhotic non-alcoholic steatohepati…
Boehringer Ingelheim International GmbH - A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition
Regeneron Pharmaceuticals, Inc. · Recruiting · NCT05519475 - 17 b-hydroxysteroid dehydrogenase type 13 minimization for the treatme
GlaxoSmithKline, LLC. - A dose-finding, double-blind, placebo-controlled phase 2 study to eva
GlaxoSmithKline, LLC. - A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Eli Lilly and Company · Completed · NCT05395481 - A Randomized DoubleBlind Parallel Group Multi Center Phase III Study to Assess the Efficacy of Budesonide Glycopyrronium and Formoterol Fumarate MeterednDose Inhaler Relative to Glycopyrronium and Formoterol Fumarate …
AstraZeneca Pharmaceuticals LP - LX9211.1-204-DPN
Lexicon Pharmaceuticals, Inc. - A phase 2B multicenter randomized doubleblind placebocontrolled study to evaluate the efficacy and safety of onceweekly MET097 in adults with obesity or overweight and type 2 diabetes mellitus VESPER2
Pfizer Inc. - A Phase 2b3 Randomized, Double blind, Placebo controlled Study to Evaluate the Safety and Efficacy of Cotadutide in Participants with Non cirrhotic Non alcoholic Steatohepatitis with Fibrosis
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.